Vivendy Therapeutics

The company's strategy centered on creating a biopharmaceutical drug for a condition with no existing therapy. This positioned Vivendy's product to potentially receive "orphan drug status," a designation that provides incentives for the development of treatments for rare diseases. The business model relied on raising significant venture capital to fund the lengthy and expensive process of drug development, from preclinical research to market introduction. A major financial milestone was achieved on June 18, 2008, when the company secured $30.5 million in a Series A funding round. This financing was led by a syndicate of prominent life science investors, including Life Sciences Partners, EQT, TVM Capital, BioMedPartners, and Aescap Venture. The then-CEO, Dr. Roland Toder, stated that this capital was intended to be sufficient to bring their lead product all the way to market introduction.

Vivendy Therapeutics' approach involved using a genetically modified form of the natural enzyme to effectively treat Morbus Morquio patients. The company's mission was to navigate the complex development path toward registration and provide a therapy for patients as quickly as possible. Despite securing substantial funding and having a clear development strategy, the company was reportedly liquidated in 2012 and is now considered deadpooled.